PROJECT

Projects

Environmental & Social Review Summary

Project Number

42489

Company Name

1MG TECHNOLOGIES PRIVATE LIMITED

Date ESRS Disclosed

Feb 28, 2019

Country

India

Region

South Asia

Last Updated Date

Jun 29, 2019

Environmental Category

B - Limited

Status

Active

Previous Events

Approved : Jun 11, 2019
Signed : Jun 18, 2019
Invested : Jun 25, 2019

Sector

other

Industry

other

Department

Disruptive Technologies and Funds

Project Description

In 2012, a digital health platform called HealthkartPlus was started as a division within BLPL (Bright Lifecare Private Limited). In 2015, this was de-merged and transferred to 1MG Technologies Private Limited (1mg or the Company).1mg is the largest digital healthcare platform in India (https://www.1mg.com/aboutUs). Since 2015, 1mg has evolved from an information-based engagement model with consumers to a broader-based healthcare platform encompassing the following:

(a)   e-pharmacy Marketplace:  The company operates an ePharmacy marketplace, which facilitates vendors across the country to sell medicines and OTC products to consumers. In larger cities, the company operates a full stack operation where it provides logistics service, call centre, order fulfilment, & payment collection support to the pharmacies, while in smaller cities it tied up with the local retailers in those markets who manage the deliveries directly or through 3rd parties. Currently, the company has two warehouses in Delhi NCR (sizes less than 12000 ft2) which are managed by a subsidiary of 1mg (Delhi Mediart Private Limited or DMPL).

 

The company has also diversified into alternate medicines including three own private label Ayurvedic medicines which are distributed through the platform as well as offline through the pharmacies (discussed below).

 

(b)   B2B Distribution (Offline pharma distribution, inventory management and collections for diagnostics):

 

  • Pharma distribution: 1mg through its subsidiary DMPL allows hospitals and standalone retail pharmacies to procure from manufacturers directly through its platform, eliminating multiple tiers of stockists and distributors. It also provides solutions for inventory management. 1mg has also been selectively taking over management of hospital pharmacies.
  • Home collection services for diagnostic labs: Sample collection and logistics support to diagnostic labs (details provided below) through its subsidiary LFS Healthcare Private Limited (“LabForSure”).
  • Industry partnerships with insurance companies: 1mg is working with insurance companies for lead generation, providing outpatient consultation coverage, providing pre-policy medical checkup services and digitising prescriptions for medicines and tests. 

 

(c)   E-diagnostics: 1mg has a marketplace that provides single window comparison across labs and facilitates scheduled home pick-ups of customer samples at the convenience of the customer and having these samples delivered directly to the diagnostic lab. It is also integrated with the various diagnostic labs to provide the customer a digital version of the report on email/app and provides a single window access to all labs.

 

1mg has also tied up with many small labs that lack large customer base and branded them as 1mg labs on the platform; currently it operates two such labs. The company has also recently launched its own centralized lab in Delhi NCR. A subsidiary of 1mg (LabForSure), which has its own employees as well as part-time employees, handles the collection and delivery of samples. 

 

(d)   E-consultations: Through the doctors on contract, partners with several super-specialists and other general practitioners, 1mg offers medical consults to patients via 1MG's app platform.

 

The proposed investment is an equity investment for (“the project”) (i) rollout of its e-pharmacy, e-diagnostics and pharma distribution to underserved cities (ii) increasing share of full stack model in large cities to improve fill rates and turnaround times (TAT) (iii) improving product mix; (iv) expanding bouquet of diagnostic services and (v)investing in brand building.

Overview of IFC's Scope of Review

IFC’s review of the proposed investment consisted of appraising technical, environmental, health and safety (EHS) and social information submitted by 1mg/DMPL/LabForSure including on EHS permits, Human Resource (HR) policies, and other EHS procedures. In addition, discussions with held with the company’s senior management including co-founders, chief operating officer, representatives from HR, legal and compliance, sourcing/category and laboratory operations. The appraisal also included site visits in February 2019 to 1mg’s - warehouse and laboratory in Gurugram, Haryana.

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan